Business Context and Reporting Period
Company: AnaptysBio, Inc. (ANAB)
Filing Type: Form 8-K (Current Report)
Date of Report: November 4, 2021
Reporting Period: This filing announces financial results for the three and nine months ended September 30, 2021.
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) containing the actual financial data. Consequently, the filing text itself does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material changes or comparative financial data are detailed within the body of this Form 8-K. The document solely references the issuance of a press release regarding the results for the periods ended September 30, 2021.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the issuance of a press release on November 4, 2021, but does not include the text of the commentary, guidance, or outlook.
Risks and Contingencies: No specific risks or contingencies are described in this excerpt.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other registration statements unless expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (the attached press release) for specific revenue, net loss, and cash position figures for the three and nine months ended September 30, 2021.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or partnership milestones mentioned in the referenced press release.
- Confirm the status of the company's common stock trading on The Nasdaq Stock Market LLC under the symbol ANAB.